title: Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.
abstract: CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.
authors.affiliation: Translational Research Program and Department of Pathology and Laboratory Medicine; Abramson Cancer Center; Perelman School of Medicine; University of Pennsylvania ; Philadelphia, PA USA.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Johnson
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC USA.
authors.forename: Luis
authors.initials: L
authors.lastname: Sanchez-Perez
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC USA.
authors.forename: Carter M
authors.initials: CM
authors.lastname: Suryadevara
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center ; Durham, NC USA.
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
keywords: adoptive cell therapy; cancer immunology; chimeric antigen receptor; gene-engineering; glioblastoma; tumor immunotherapy